Nuevo dispositivo para medición del FFR permite cruzar la lesión con nuestra guía preferida

Use of Transjugular Echocardiography in TAVR

TAVR is a well-established course of treatment, increasingly indicated in lower risk populations. However, one of the challenges associated with self-expanding TAVR, compared against balloon expandable TAVR and SAVR, is the frequent need for definite permanent pacemaker implantation (PPI).  High implantation, also known as cusp overlapping (COT), has been shown to reduce the need for<a href="https://solaci.org/en/2024/03/06/use-of-transjugular-echocardiography-in-tavr/" title="Read more" >...</a>

Post TAVR Long Term Outcomes in Patients with Chronic Inflammatory Disease

Patients suffering from immune-mediated chronic inflammatory disease (CID) face a high risk of developing heart disease, including aortic valve disease. Inflammatory vascular disease when triggered by an autoimmune condition, can prompt a harmful response leading to valve degeneration, with increased calcification and fibrosis, and the associated progression of stenosis, failure or both.  Prior research has<a href="https://solaci.org/en/2024/03/04/post-tavr-long-term-outcomes-in-patients-with-chronic-inflammatory-disease/" title="Read more" >...</a>

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

Edge-to-Edge Repair in Cardiogenic Shock

The edge-to-edge approach with MitraClip has been established as a valid strategy for patients who experience severe symptomatic mitral regurgitation (MI) with high risk for surgery, currently with a IIa indication. MI complicated by cardiogenic shock, which results in a high risk for conventional valve surgery, is a particularly complex scenario. In such a case,<a href="https://solaci.org/en/2024/02/26/edge-to-edge-repair-in-cardiogenic-shock/" title="Read more" >...</a>

Short-Term Outcomes of TAVR in Asymptomatic or Minimally Symptomatic Patients

Aortic valve replacement (AVR) is indicated for symptomatic aortic stenosis (AS), while close follow-up is recommended for asymptomatic patients, unless they have elevated aortic gradients, low ejection fraction, or abnormal stress tests. However, the optimal timing to perform AVR is uncertain, especially with recent evidence suggesting that patients with AS associated with signs of myocardial<a href="https://solaci.org/en/2024/02/21/short-term-outcomes-of-tavr-in-asymptomatic-or-minimally-symptomatic-patients/" title="Read more" >...</a>

TAVR in Low Risk Patients: 10 Year Evolution

The Treatment of severe aortic stenosis has experienced a significant revolution with TAVR, especially in high and intermediate risk patients, and it is now extending to low risk patients. In the US, nearly half of patients under 64 are being treated with TAVR.  One of the fundamental questions that still remains unanswered revolves around device<a href="https://solaci.org/en/2024/02/14/tavr-in-low-risk-patients-10-year-evolution/" title="Read more" >...</a>

Sobrevida en pacientes con insuficiencia tricuspídea según variables clínicas y ecocardiográficas (Clusters)

Should We Treat Obstructive Coronary Artery Disease in TAVI?

Coronary artery disease, both obstructive and non-obstructive, often coexists with significant aortic stenosis. Therapeutic decision-making in this scenario remains controversial, not only regarding the need for treatment, but also about when it should be addressed, considering its pros and cons. Various analyses have yielded contradictory data, as most lesions are chronic and stable. Currently, the<a href="https://solaci.org/en/2024/02/07/should-we-treat-obstructive-coronary-artery-disease-in-tavi/" title="Read more" >...</a>

Left Atrial Appendage Closure and Concomitant Transcatheter Intervention: Can We?

Several scientific societies support performing left atrial appendage occlusion (LAAO) as a stand-alone procedure, even though it is often associated to other cardiomyopathies requiring transcatheter intervention.  Though still controversial, combining LAAO and any other cardiac intervention might reduce hospitalizations, as well as the need for additional punctures, anesthesia, red tape, a longer stay and higher<a href="https://solaci.org/en/2024/02/06/left-atrial-appendage-closure-and-concomitant-transcatheter-intervention-can-we/" title="Read more" >...</a>

Does Post-Dilation in TAVR Affect its Long-Term Outcomes?

Transcatheter aortic valve replacement (TAVR) has widely demonstrated its significant benefits, both in high-risk and inoperable patients, as well as in those with intermediate and low risk. While paravalvular regurgitation has been a challenge, its management has improved with operator experience and a deeper understanding of CT angiographies. However, in cases of regurgitation, elevated gradient,<a href="https://solaci.org/en/2024/02/01/does-post-dilation-in-tavr-affect-its-long-term-outcomes/" title="Read more" >...</a>

See the Presentations of Dominican Republic Sessions 2023

The XLVI SOLACI Regional Sessions – 16th Central America and the Caribbean Region took place in Santo Domingo, Dominican Republic, between September 14 and 15, 2023. It was an extremely successful event that featured the participation of prestigious national and international guests and a high-level scientific program. Below, we share some of the presentations that<a href="https://solaci.org/en/2024/01/31/see-the-presentations-of-dominican-republic-sessions-2023/" title="Read more" >...</a>

Coronary Artery Disease in TAVR: Unsolved Dilemma

Aortic stenosis shares risk factors with coronary artery disease (CAD), and its prevalence varies according to age, reaching approximately 50% or more in some registries. Deciding when to treat and the need for percutaneous intervention presents a challenge. It has been established that epicardial stenosis at proximal level, or the medial segment, requires intervention, especially<a href="https://solaci.org/en/2024/01/30/coronary-artery-disease-in-tavr-unsolved-dilemma/" title="Read more" >...</a>